5 Key Takeaways

• 1

  All 16 patients treated with the individualized cancer vaccine remained disease-free after a median follow-up of 41 months.

• 2

  Three of the 16 patients in the control group experienced disease recurrence during the study.

• 3

  The trial focused on patients with resected, human papillomavirus-negative head and neck squamous cell carcinoma.

• 4

  The vaccine, TG4050, is tailored for each patient using tumor and normal tissue samples to identify cancer-specific mutations.

• 5

  The vaccine induced detectable T-cell responses in 73.3% of evaluated patients, with responses lasting over a year after treatment.